Issue of Equity and Total Voting Rights

RNS Number : 3894Y

Instem plc

16 May 2016

 

Instem plc
("Instem" or the "Company")

Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that, following the exercise of share options by an employee on 16 May 2016, 65,842 ordinary shares of 10p each in the Company ("Ordinary Shares") were issued.

Application will be made to the London Stock Exchange for the admission of the 65,842 new Ordinary Shares to trading on AIM and admission is expected to take place at 8.00am on 20 May 2016.

Total Voting Rights

Following the issue and allotment of the above new Ordinary Shares, the Company's issued share capital comprises 15,616,059 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,616,059.

The figure of 15,616,059 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	[phone]
Richard Lindley
Nick Owen
James White
Walbrook Financial PR	[phone]
Paul Cornelius	[e-mail]
Helen Cresswell
Sam Allen
Paul Whittington

About Instem plc

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, the United Kingdom, India and China, with additional presence in France and Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com

 

END

 

 

MSCEASSKFANKEFF